Phase 2 AMG 714 in Rheumatoid Arthritis

This study has been completed.
Information provided by:
Amgen Identifier:
First received: February 8, 2007
Last updated: December 20, 2007
Last verified: December 2007
Twelve week treatment of AMG 714 in RA patients who failed at least one DMARD, followed by a 3 month observational period.

Condition Intervention Phase
Rheumatoid Arthritis
Drug: AMG 714
Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double-Blind
Primary Purpose: Treatment
Official Title: A Double-Blind, Placebo Controlled, Randomized, Parallel-Group Clinical Trial With Multiple Dose Treatment of Anti-IL 15 Human Monoclonal Antibody (AMG 714) in Patients With Active Rheumatoid Arthritis Who Have Previously Failed One or More Disease Modifying Anti-Rheumatic Drugs

Resource links provided by NLM:

Further study details as provided by Amgen:

Estimated Enrollment: 180
Study Start Date: December 2002

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both

Inclusion Criteria: Diagnosis of RA -

Exclusion Criteria: No prior biologic treatment for RA

  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00433875

Sponsors and Collaborators
Study Director: MD Amgen
  More Information

Additional Information:
Responsible Party: Global Development Leader, Amgen Inc. Identifier: NCT00433875     History of Changes
Other Study ID Numbers: 20030210 
Study First Received: February 8, 2007
Last Updated: December 20, 2007
Health Authority: Denmark: Ministry of Health
Germany: Federal Institute for Drugs and Medical Devices
Poland: Drug Institut
South Africa: Department of Health
Sweden: Medical Products Agency
United Kingdom: Medicines and Healthcare Products Regulatory Agency
United States: Food and Drug Administration

Additional relevant MeSH terms:
Arthritis, Rheumatoid
Autoimmune Diseases
Connective Tissue Diseases
Immune System Diseases
Joint Diseases
Musculoskeletal Diseases
Rheumatic Diseases processed this record on May 26, 2016